Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.51 |
| ▸ | PGR | P06401 | 7/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488661 | 0.96 | NR3C2 (0.48) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488305 | 0.92 | PGR (0.43) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488254 | 0.85 | PGR (0.50) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488293 | 0.85 | NR3C2 (0.39) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3489968 | 0.85 | NR3C2 (0.48) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3489385 | 0.84 | SMPD1 (0.46) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3487986 | 0.84 | NR3C2 (0.39) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488225 | 0.84 | NR3C2 (0.49) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488178 | 0.83 | MAPT (0.41) | NR3C2PGRARMAPTALDH1A1 | |
| SCHEMBL3488809 | 0.82 | ALDH1A1 (0.39) | NR3C2PGRARMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | NR3C2 1/4885PGR 107/4885AR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.